A detailed history of Tower Research Capital LLC (Trc) transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 2,635 shares of BMEA stock, worth $11,594. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,635
Previous 24,392 89.2%
Holding current value
$11,594
Previous $109,000 76.15%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.23 - $10.1 $92,032 - $219,745
-21,757 Reduced 89.2%
2,635 $26,000
Q2 2024

Aug 13, 2024

BUY
$4.14 - $15.3 $99,148 - $366,419
23,949 Added 5406.09%
24,392 $109,000
Q1 2024

May 15, 2024

SELL
$13.92 - $19.5 $214,117 - $299,949
-15,382 Reduced 97.2%
443 $6,000
Q4 2023

Feb 13, 2024

BUY
$8.37 - $19.8 $105,244 - $248,965
12,574 Added 386.77%
15,825 $229,000
Q3 2023

Nov 14, 2023

BUY
$13.44 - $23.02 $33,196 - $56,859
2,470 Added 316.26%
3,251 $44,000
Q2 2023

Aug 14, 2023

SELL
$21.66 - $41.8 $24,627 - $47,526
-1,137 Reduced 59.28%
781 $17,000
Q1 2023

May 09, 2023

SELL
$6.8 - $32.35 $5,888 - $28,015
-866 Reduced 31.11%
1,918 $59,000
Q4 2022

Feb 10, 2023

SELL
$6.3 - $11.6 $35,267 - $64,936
-5,598 Reduced 66.79%
2,784 $23,000
Q3 2022

Nov 10, 2022

BUY
$9.51 - $13.61 $67,521 - $96,631
7,100 Added 553.82%
8,382 $82,000
Q2 2022

Aug 15, 2022

SELL
$3.0 - $12.03 $3,165 - $12,691
-1,055 Reduced 45.14%
1,282 $15,000
Q1 2022

May 12, 2022

BUY
$4.39 - $9.03 $2,269 - $4,668
517 Added 28.41%
2,337 $10,000
Q4 2021

Feb 14, 2022

BUY
$7.22 - $12.72 $5,797 - $10,214
803 Added 78.96%
1,820 $14,000
Q3 2021

Nov 15, 2021

BUY
$10.0 - $15.99 $9,560 - $15,286
956 Added 1567.21%
1,017 $12,000
Q2 2021

Aug 16, 2021

BUY
$13.65 - $20.93 $832 - $1,276
61 New
61 $1,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $129M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.